44-301 : Special Drug Use-Results Survey of VELEXBRU (PCNSL)

44-301 : Special Drug Use-Results Survey of VELEXBRU(relapsed or refractory primary central nervous system lymphoma (PCNSL))

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2011210002

Enrollment

100

Registered

2021-04-16

Start date

2020-05-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

relapsed or refractory primary central nervous system lymphoma (PCNSL)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients with PCSNL for whom VELEXBLU is administered

Exclusion criteria

Exclusion criteria: patients who have not received VELEXBLU

Design outcomes

Primary

Measure	Time frame
Occurrence status of adverse drug reactions and infections, Occurrence status of adverse drug reactions corresponding to specified safety concerns, Factors that are considered to affect safety Specified safety concerns: Infections,Severe skin disorders, Myelosuppression, Hypersensitivity, Interstitial lung diseases, Hepatic function disorders, Hemorrhage	—

Contacts

Public ContactTakafumi Nakao

Ono Pharmaceutical Co.,LTD

pms_contact_ml@ono-pharma.com+81-6-6222-5501

Outcome results